Contineum Therapeutics, Inc. (CTNM) stock
CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.86+0.08 (+0.82%)
Close on Nov 13, 2026Market cap $370.94MP/E –Yield –
Contineum Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Contineum Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$66.00M. For fiscal 2025 it was -$67.74M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$67.74M | – |
| FY2024 | Dec 31, 2024 | -$50.64M | -411.2% |
| FY2023 | Dec 31, 2023 | $16.27M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.82M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.82M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.03M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.91M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.88M | -127.9% |
| Q1 FY2024 | Mar 31, 2024 | -$9.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.03M | – |
| Q2 FY2023 | Jun 30, 2023 | $38.98M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.04M | – |
See a number that looks wrong?